Carfilzomib May Offer Advantages in Patients with Relapsed/Refractory Multiple Myeloma - The ASCO Post
Efficacy and safety profile of deep responders to carfilzomib-based therapy: a subgroup analysis from ASPIRE and ENDEAVOR | Leukemia
Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR - ScienceDirect
Efficacy and Safety of Carfilzomib, Lenalidomide and Dexamethasone in MM | Research To Practice
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment | Blood Cancer Journal
Takeda Oncology on Twitter: "Multiple #myeloma may be the most common, but DYK there are several other forms of myeloma? Take action, learn more https://t.co/aDKofURa4c https://t.co/aFizSxMTn0" / Twitter
The emerging therapeutic landscape of relapsed/refractory multiple myeloma | SpringerLink
Optimising Treatment in Relapsed, Refractory Multiple Myeloma | touchONCOLOGY
Elotuzumab - A Closer Look At The ELOQUENT-2 Clinical Trial Results
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials - ScienceDirect
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial - The Lancet Oncology
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation. - ppt download
Carfilzomib in multiple myeloma
Additional Abstracts of Interest in Multiple Myeloma at ASH 2015 | Research To Practice
Carfilzomib with immunomodulatory drugs for the treatment of newly diagnosed multiple myeloma | Leukemia
Current Oncology | Free Full-Text | Relapsed/Refractory Multiple Myeloma: A Review of Available Therapies and Clinical Scenarios Encountered in Myeloma Relapse
Frontiers | Carfilzomib: A Promising Proteasome Inhibitor for the Treatment of Relapsed and Refractory Multiple Myeloma
Kyprolis Label to Include Positive Data of Aspire Trial in Advanced Multiple Myeloma Patients
Design of randomized phase 3 trials. A, ASPIRE trial; B, ENDEAVOR... | Download Scientific Diagram
Carfilzomib Benefits Outweigh Potential for Cardiac Toxicity in Relapsed/Refractory Myeloma
Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma | NEJM
Amgen's Phase III ASPIRE trial of myeloma treatment Kyprolis meets primary endpoint - Clinical Trials Arena
Interim Results of ASPIRE Trial | Int'l Myeloma Fndn
